Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition
This study provides the first evidence that inhibiting mitochondrial translation with linezolid ameliorates fibrotic tissue remodeling. Because linezolid is already clinically approved as a reserve antibiotic, these findings hold translational promise and support the use of linezolid as a novel treatment for fibrotic disorders after further validation.
Authors
- Xuezhi Hong (ORCID: https://orcid.org/0000-0002-3268-7404)
- Jörg H. W. Distler (ORCID: https://orcid.org/0000-0001-7408-9333)
- Clara Dees (ORCID: https://orcid.org/0000-0001-5443-0602)
- Yanhua Xiao (ORCID: https://orcid.org/0000-0001-8014-1740)
- Shihao Zhu (ORCID: https://orcid.org/0009-0008-9973-9871)
- Thuong Trinh‐Minh (ORCID: https://orcid.org/0009-0008-3345-3694)
- Alexandru‐Emil Matei (ORCID: https://orcid.org/0000-0003-1248-3145)
- Georg Andreas Schett (ORCID: https://orcid.org/0000-0001-8740-9615)
- Andrea‐Hermina Györfi (ORCID: https://orcid.org/0000-0002-4960-3369)
- Tim Filla (ORCID: https://orcid.org/0000-0001-5628-8398)
- Haodong Qi
- Zhi Li (ORCID: https://orcid.org/0000-0002-6437-0348)
- Yinan Li (ORCID: https://orcid.org/0000-0001-8934-9361)
- Meilin Xu
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Zero to Three (US)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1002/art.43440
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00